Abstract
The development of peptide-based HIV entry inhibitors has made an important contribution to the stock of anti-HIV drugs. In particular, the peptide-based anti-HIV drugs enfuvirtide and albuvirtide were approved for clinical use by the U.S. FDA and CFDA in 2003 and 2018, respectively. Peptide-based HIV entry inhibitors exert antiviral activity by targeting the early stage of viral infection, i.e., binding of a viral surface protein to the receptor(s) on the host cell and the subsequent fusion between the viral and host cell membranes. Therefore, they are particularly useful for HIV-infected patients who have failed to respond to the highly active antiretroviral drugs (ARD) targeting the late stage of HIV replication, such as reverse transcriptase inhibitors and protease inhibitors. In this chapter, we will focus on the past, current, and future trends in research and development of peptide-based HIV entry inhibitors.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Aneja R, Rashad AA, Li H, Kalyana Sundaram RV, Duffy C, Bailey LD, Chaiken I (2015) Peptide triazole inactivators of HIV-1 utilize a conserved two-cavity binding site at the junction of the inner and outer domains of Env gp120. J Med Chem 58(9):3843–3858. https://doi.org/10.1021/acs.jmedchem.5b00073
Ávila-Ríos S, García-Morales C, Matías-Florentino M, Romero-Mora KA, Tapia-Trejo D, Quiroz-Morales VS, Reyes-Gopar H, Ji H, Sandstrom P, Casillas-Rodríguez J, Sierra-Madero J, León-Juárez EA, Valenzuela-Lara M, Magis-Rodríguez C, Uribe-Zuñiga P, Reyes-Terán G (2016) Pretreatment HIV-drug resistance in Mexico and its impact on the effectiveness of first-line antiretroviral therapy: a nationally representative 2015 who survey. Lancet HIV 3(12):e579–e591. https://doi.org/10.1016/s2352-3018(16)30119-9
Baleux F, Loureiro-Morais L, Hersant Y, Clayette P, Arenzana-Seisdedos F, Bonnaffé D, Lortat-Jacob H (2009) A synthetic CD4-heparan sulfate glycoconjugate inhibits CCR5 and CXCR4 HIV-1 attachment and entry. Nat Chem Biol 5(10):743–748. https://doi.org/10.1038/nchembio.207
Bashir T, Patgaonkar M, Kumar SC, Pasi A, Reddy KV (2015) HBAHP-25, an in-silico designed peptide, inhibits HIV-1 entry by blocking gp120 binding to CD4 receptor. PLoS One 10(4):e0124839. https://doi.org/10.1371/journal.pone.0124839
Bastian AR, Kantharaju, McFadden K, Duffy C, Rajagopal S, Contarino MR, Papazoglou E, Chaiken I (2011) Cell-free HIV-1 virucidal action by modified peptide triazole inhibitors of Env gp120. ChemMedChem 6(8):1335–1339, 1318. https://doi.org/10.1002/cmdc.201100177
Bastian AR, Contarino M, Bailey LD, Aneja R, Moreira DR, Freedman K, McFadden K, Duffy C, Emileh A, Leslie G, Jacobson JM, Hoxie JA, Chaiken I (2013) Interactions of peptide triazole thiols with Env gp120 induce irreversible breakdown and inactivation of HIV-1 virions. Retrovirology 10:153. https://doi.org/10.1186/1742-4690-10-153
Biorn AC, Cocklin S, Madani N, Si Z, Ivanovic T, Samanen J, Van Ryk DI, Pantophlet R, Burton DR, Freire E, Sodroski J, Chaiken IM (2004) Mode of action for linear peptide inhibitors of HIV-1 gp120 interactions. Biochemistry 43(7):1928–1938. https://doi.org/10.1021/bi035088i
Bobardt MD, Cheng G, de Witte L, Selvarajah S, Chatterji U, Sanders-Beer BE, Geijtenbeek TB, Chisari FV, Gallay PA (2008) Hepatitis C virus NS5a anchor peptide disrupts human immunodeficiency virus. Proc Natl Acad Sci U S A 105(14):5525–5530. https://doi.org/10.1073/pnas.0801388105
Chan DC, Fass D, Berger JM, Kim PS (1997) Core structure of gp41 from the HIV envelope glycoprotein. Cell 89(2):263–273. https://doi.org/10.1016/s0092-8674(00)80205-6
Chinnadurai R, Rajan D, Münch J, Kirchhoff F (2007) Human immunodeficiency virus type 1 variants resistant to first- and second-version fusion inhibitors and cytopathic in ex vivo human lymphoid tissue. J Virol 81(12):6563–6572. https://doi.org/10.1128/jvi.02546-06
Choi YH, Rho WS, Kim ND, Park SJ, Shin DH, Kim JW, Im SH, Won HS, Lee CW, Chae CB, Sung YC (2001) Short peptides with induced beta-turn inhibit the interaction between HIV-1 gp120 and CD4. J Med Chem 44(9):1356–1363. https://doi.org/10.1021/jm000403+
Chong H, Yao X, Qiu Z, Qin B, Han R, Waltersperger S, Wang M, Cui S, He Y (2012) Discovery of critical residues for viral entry and inhibition through structural insight of HIV-1 fusion inhibitor CP621-652. J Biol Chem 287(24):20281–20289. https://doi.org/10.1074/jbc.M112.354126
Chong H, Yao X, Qiu Z, Sun J, Zhang M, Waltersperger S, Wang M, Liu SL, Cui S, He Y (2013) Short-peptide fusion inhibitors with high potency against wild-type and enfuvirtide-resistant HIV-1. FASEB J 27(3):1203–1213. https://doi.org/10.1096/fj.12-222547
Chong H, Qiu Z, Su Y, Yang L, He Y (2015) Design of a highly potent HIV-1 fusion inhibitor targeting the gp41 pocket. AIDS 29(1):13–21. https://doi.org/10.1097/qad.0000000000000498
Chong H, Wu X, Su Y, He Y (2016) Development of potent and long-acting HIV-1 fusion inhibitors. AIDS 30(8):1187–1196. https://doi.org/10.1097/qad.0000000000001073
Chong H, Xue J, Zhu Y, Cong Z, Chen T, Guo Y, Wei Q, Zhou Y, Qin C, He Y (2018a) Design of novel HIV-1/2 fusion inhibitors with high therapeutic efficacy in rhesus monkey models. J Virol 92(16):e00775–e00718. https://doi.org/10.1128/jvi.00775-18
Chong H, Zhu Y, Yu D, He Y (2018b) Structural and functional characterization of membrane fusion inhibitors with extremely potent activity against human immunodeficiency virus type 1 (HIV-1), HIV-2, and simian immunodeficiency virus. J Virol 92(20):e01088–e01018. https://doi.org/10.1128/jvi.01088-18
Chong H, Xue J, Zhu Y, Cong Z, Chen T, Wei Q, Qin C, He Y (2019) Monotherapy with a low-dose lipopeptide HIV fusion inhibitor maintains long-term viral suppression in rhesus macaques. PLoS Pathog 15(2):e1007552. https://doi.org/10.1371/journal.ppat.1007552
Cimbro R, Peterson FC, Liu Q, Guzzo C, Zhang P, Miao H, Van Ryk D, Ambroggio X, Hurt DE, De Gioia L, Volkman BF, Dolan MA, Lusso P (2016) Tyrosine-sulfated V2 peptides inhibit HIV-1 infection via coreceptor mimicry. EBioMedicine 10:45–54. https://doi.org/10.1016/j.ebiom.2016.06.037
Connell BJ, Baleux F, Coic YM, Clayette P, Bonnaffé D, Lortat-Jacob H (2012) A synthetic heparan sulfate-mimetic peptide conjugated to a mini CD4 displays very high anti-HIV-1 activity independently of coreceptor usage. Chem Biol 19(1):131–139. https://doi.org/10.1016/j.chembiol.2011.12.009
Cormier EG, Persuh M, Thompson DA, Lin SW, Sakmar TP, Olson WC, Dragic T (2000) Specific interaction of CCR5 amino-terminal domain peptides containing sulfotyrosines with HIV-1 envelope glycoprotein gp120. Proc Natl Acad Sci U S A 97(11):5762–5767. https://doi.org/10.1073/pnas.97.11.5762
De Clercq E (2002) New anti-HIV agents and targets. Med Res Rev 22(6):531–565. https://doi.org/10.1002/med.10021
De Rossi A, Pasti M, Mammano F, Panozzo M, Dettin M, Di Bello C, Chieco-Bianchi L (1991) Synthetic peptides from the principal neutralizing domain of human immunodeficiency virus type 1 (HIV-1) enhance HIV-1 infection through a CD4-dependent mechanism. Virology 184(1):187–196. https://doi.org/10.1016/0042-6822(91)90835-y
Ding X, Zhang X, Chong H, Zhu Y, Wei H, Wu X, He J, Wang X, He Y (2017) Enfuvirtide (T20)-based lipopeptide is a potent HIV-1 cell fusion inhibitor: implications for viral entry and inhibition. J Virol 91(18):e00831–e00817. https://doi.org/10.1128/jvi.00831-17
Dogo-Isonagie C, Lam S, Gustchina E, Acharya P, Yang Y, Shahzad-ul-Hussan S, Clore GM, Kwong PD, Bewley CA (2012) Peptides from second extracellular loop of C-C chemokine receptor type 5 (CCR5) inhibit diverse strains of HIV-1. J Biol Chem 287(18):15076–15086. https://doi.org/10.1074/jbc.M111.332361
Dwyer JJ, Wilson KL, Davison DK, Freel SA, Seedorff JE, Wring SA, Tvermoes NA, Matthews TJ, Greenberg ML, Delmedico MK (2007) Design of helical, oligomeric HIV-1 fusion inhibitor peptides with potent activity against enfuvirtide-resistant virus. Proc Natl Acad Sci U S A 104(31):12772–12777. https://doi.org/10.1073/pnas.0701478104
Eissmann K, Mueller S, Sticht H, Jung S, Zou P, Jiang S, Gross A, Eichler J, Fleckenstein B, Reil H (2013) HIV-1 fusion is blocked through binding of Gb virus C E2-derived peptides to the HIV-1 gp41 disulfide loop [corrected]. PLoS One 8(1):e54452. https://doi.org/10.1371/journal.pone.0054452
Farzan M, Vasilieva N, Schnitzler CE, Chung S, Robinson J, Gerard NP, Gerard C, Choe H, Sodroski J (2000) A tyrosine-sulfated peptide based on the n terminus of CCR5 interacts with a CD4-enhanced epitope of the HIV-1 gp120 envelope glycoprotein and inhibits HIV-1 entry. J Biol Chem 275(43):33516–33521. https://doi.org/10.1074/jbc.M007228200
Ferrer M, Harrison SC (1999) Peptide ligands to human immunodeficiency virus type 1 gp120 identified from phage display libraries. J Virol 73(7):5795–5802. https://doi.org/10.1128/jvi.73.7.5795-5802.1999
Furci L, Sironi F, Tolazzi M, Vassena L, Lusso P (2007) Alpha-defensins block the early steps of HIV-1 infection: interference with the binding of gp120 to CD4. Blood 109(7):2928–2935. https://doi.org/10.1182/blood-2006-05-024489
Galatola R, Vasconcelos A, Pérez Y, Cruz A, Pujol M, Alsina MA, Gómara MJ, Haro I (2014) A cyclic gb virus C derived peptide with anti-HIV-1 activity targets the fusion peptide of HIV-1. Eur J Med Chem 86:589–604. https://doi.org/10.1016/j.ejmech.2014.09.020
Gómara MJ, Galatola R, Gutiérrez A, Gimeno MC, Gatell JM, Sánchez-Merino V, Yuste E, Haro I (2014) HIV-1 inhibiting capacity of novel forms of presentation of gb virus c peptide domains is enhanced by coordination to gold compounds. Curr Med Chem 21(2):238–250. https://doi.org/10.2174/09298673113206660276
Gómara MJ, Sánchez-Merino V, Paús A, Merino-Mansilla A, Gatell JM, Yuste E, Haro I (2016) Definition of an 18-mer synthetic peptide derived from the gb virus c e1 protein as a new hiv-1 entry inhibitor. Biochim Biophys Acta 1860(6):1139–1148. https://doi.org/10.1016/j.bbagen.2016.02.008
Gopi H, Umashankara M, Pirrone V, LaLonde J, Madani N, Tuzer F, Baxter S, Zentner I, Cocklin S, Jawanda N, Miller SR, Schön A, Klein JC, Freire E, Krebs FC, Smith AB, Sodroski J, Chaiken I (2008) Structural determinants for affinity enhancement of a dual antagonist peptide entry inhibitor of human immunodeficiency virus type-1. J Med Chem 51(9):2638–2647. https://doi.org/10.1021/jm070814r
Gopi H, Cocklin S, Pirrone V, McFadden K, Tuzer F, Zentner I, Ajith S, Baxter S, Jawanda N, Krebs FC, Chaiken IM (2009) Introducing metallocene into a triazole peptide conjugate reduces its off-rate and enhances its affinity and antiviral potency for HIV-1 gp120. J Mol Recognit 22(2):169–174. https://doi.org/10.1002/jmr.892
Groß A, Brox R, Damm D, Tschammer N, Schmidt B, Eichler J (2015) Ligand selectivity of a synthetic CXCR4 mimetic peptide. Bioorg Med Chem 23(14):4050–4055. https://doi.org/10.1016/j.bmc.2015.03.003
He Y, Xiao Y, Song H, Liang Q, Ju D, Chen X, Lu H, Jing W, Jiang S, Zhang L (2008) Design and evaluation of sifuvirtide, a novel HIV-1 fusion inhibitor. J Biol Chem 283(17):11126–11134. https://doi.org/10.1074/jbc.M800200200
Herrera E, Tenckhoff S, Gómara MJ, Galatola R, Bleda MJ, Gil C, Ercilla G, Gatell JM, Tillmann HL, Haro I (2010) Effect of synthetic peptides belonging to E2 envelope protein of gb virus C on human immunodeficiency virus type 1 infection. J Med Chem 53(16):6054–6063. https://doi.org/10.1021/jm100452c
Huang CC, Stricher F, Martin L, Decker JM, Majeed S, Barthe P, Hendrickson WA, Robinson J, Roumestand C, Sodroski J, Wyatt R, Shaw GM, Vita C, Kwong PD (2005) Scorpion-toxin mimics of CD4 in complex with human immunodeficiency virus gp120 crystal structures, molecular mimicry, and neutralization breadth. Structure 13(5):755–768. https://doi.org/10.1016/j.str.2005.03.006
Ingallinella P, Bianchi E, Ladwa NA, Wang YJ, Hrin R, Veneziano M, Bonelli F, Ketas TJ, Moore JP, Miller MD, Pessi A (2009) Addition of a cholesterol group to an hiv-1 peptide fusion inhibitor dramatically increases its antiviral potency. Proc Natl Acad Sci U S A 106(14):5801–5806. https://doi.org/10.1073/pnas.0901007106
Jiang S, Lin K, Strick N, Neurath AR (1993) HIV-1 inhibition by a peptide. Nature 365(6442):113. https://doi.org/10.1038/365113a0
Koedel Y, Eissmann K, Wend H, Fleckenstein B, Reil H (2011) Peptides derived from a distinct region of gb virus C glycoprotein E2 mediate strain-specific HIV-1 entry inhibition. J Virol 85(14):7037–7047. https://doi.org/10.1128/jvi.02366-10
Lalezari JP, Henry K, O’Hearn M, Montaner JS, Piliero PJ, Trottier B, Walmsley S, Cohen C, Kuritzkes DR, Eron JJ Jr, Chung J, DeMasi R, Donatacci L, Drobnes C, Delehanty J, Salgo M (2003) Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N Engl J Med 348(22):2175–2185. https://doi.org/10.1056/NEJMoa035026
Lorin C, Saidi H, Belaid A, Zairi A, Baleux F, Hocini H, Bélec L, Hani K, Tangy F (2005) The antimicrobial peptide dermaseptin s4 inhibits hiv-1 infectivity in vitro. Virology 334(2):264–275. https://doi.org/10.1016/j.virol.2005.02.002
Lu M, Blacklow SC, Kim PS (1995) A trimeric structural domain of the HIV-1 transmembrane glycoprotein. Nat Struct Biol 2(12):1075–1082. https://doi.org/10.1038/nsb1295-1075
Maggi P, Ladisa N, Cinori E, Altobella A, Pastore G, Filotico R (2004) Cutaneous injection site reactions to long-term therapy with enfuvirtide. J Antimicrob Chemother 53(4):678–681. https://doi.org/10.1093/jac/dkh141
Martin L, Stricher F, Missé D, Sironi F, Pugnière M, Barthe P, Prado-Gotor R, Freulon I, Magne X, Roumestand C, Ménez A, Lusso P, Veas F, Vita C (2003) Rational design of a CD4 mimic that inhibits HIV-1 entry and exposes cryptic neutralization epitopes. Nat Biotechnol 21(1):71–76. https://doi.org/10.1038/nbt768
Martin-Carbonero L (2004) Discontinuation of the clinical development of fusion inhibitor T-1249. AIDS Rev 6(1):61
McFadden K, Fletcher P, Rossi F, Kantharaju, Umashankara M, Pirrone V, Rajagopal S, Gopi H, Krebs FC, Martin-Garcia J, Shattock RJ, Chaiken I (2012) Antiviral breadth and combination potential of peptide triazole HIV-1 entry inhibitors. Antimicrob Agents Chemother 56(2):1073–1080. https://doi.org/10.1128/aac.05555-11
Möbius K, Dürr R, Haussner C, Dietrich U, Eichler J (2012) A functionally selective synthetic mimic of the HIV-1 co-receptor CXCR4. Chemistry 18(27):8292–8295. https://doi.org/10.1002/chem.201200111
Munch J, Standker L, Adermann K, Schulz A, Schindler M, Chinnadurai R, Pohlmann S, Chaipan C, Biet T, Peters T, Meyer B, Wilhelm D, Lu H, Jing W, Jiang S, Forssmann WG, Kirchhoff F (2007) Discovery and optimization of a natural HIV-1 entry inhibitor targeting the gp41 fusion peptide. Cell 129(2):263–275. https://doi.org/10.1016/j.cell.2007.02.042
Nehete PN, Arlinghaus RB, Sastry KJ (1993) Inhibition of human immunodeficiency virus type 1 infection and syncytium formation in human cells by V3 loop synthetic peptides from gp120. J Virol 67(11):6841–6846. https://doi.org/10.1128/jvi.67.11.6841-6846.1993
Otaka A, Nakamura M, Nameki D, Kodama E, Uchiyama S, Nakamura S, Nakano H, Tamamura H, Kobayashi Y, Matsuoka M, Fujii N (2002) Remodeling of gp41-c34 peptide leads to highly effective inhibitors of the fusion of HIV-1 with target cells. Angew Chem Int Ed Engl 41(16):2937–2940. https://doi.org/10.1002/1521-3773(20020816)41:16<2937::AID-ANIE2937>3.0.CO;2-J
Pérez Y, Gómara MJ, Yuste E, Gómez-Gutierrez P, Pérez JJ, Haro I (2017) Structural study of a new HIV-1 entry inhibitor and interaction with the HIV-1 fusion peptide in dodecylphosphocholine micelles. Chemistry 23(48):11703–11713. https://doi.org/10.1002/chem.201702531
Rosemary Bastian A, Nangarlia A, Bailey LD, Holmes A, Kalyana Sundaram RV, Ang C, Moreira DR, Freedman K, Duffy C, Contarino M, Abrams C, Root M, Chaiken I (2015) Mechanism of multivalent nanoparticle encounter with HIV-1 for potency enhancement of peptide triazole virus inactivation. J Biol Chem 290(1):529–543. https://doi.org/10.1074/jbc.M114.608315
Sakaida H, Hori T, Yonezawa A, Sato A, Isaka Y, Yoshie O, Hattori T, Uchiyama T (1998) T-tropic human immunodeficiency virus type 1 (HIV-1)-derived V3 loop peptides directly bind to CXCR-4 and inhibit T-tropic HIV-1 infection. J Virol 72(12):9763–9770. https://doi.org/10.1128/jvi.72.12.9763-9770.1998
Sánchez-Martín MJ, Hristova K, Pujol M, Gómara MJ, Haro I, Alsina MA, Busquets MA (2011a) Analysis of HIV-1 fusion peptide inhibition by synthetic peptides from E1 protein of gb virus C. J Colloid Interface Sci 360(1):124–131. https://doi.org/10.1016/j.jcis.2011.04.053
Sánchez-Martín MJ, Urbán P, Pujol M, Haro I, Alsina MA, Busquets MA (2011b) Biophysical investigations of GBV-C E1 peptides as potential inhibitors of HIV-1 fusion peptide. ChemPhysChem 12(15):2816–2822. https://doi.org/10.1002/cphc.201100407
Selhorst P, Grupping K, Tong T, Crooks ET, Martin L, Vanham G, Binley JM, Ariën KK (2013) M48U1 CD4 mimetic has a sustained inhibitory effect on cell-associated HIV-1 by attenuating virion infectivity through gp120 shedding. Retrovirology 10:12. https://doi.org/10.1186/1742-4690-10-12
Su S, Ma Z, Hua C, Li W, Lu L, Jiang S (2017a) Adding an artificial tail-anchor to a peptide-based HIV-1 fusion inhibitor for improvement of its potency and resistance profile. Molecules 22(11):1996. https://doi.org/10.3390/molecules22111996
Su S, Zhu Y, Ye S, Qi Q, Xia S, Ma Z, Yu F, Wang Q, Zhang R, Jiang S, Lu L (2017b) Creating an artificial tail anchor as a novel strategy to enhance the potency of peptide-based HIV fusion inhibitors. J Virol 91(1):e01445–e01416. https://doi.org/10.1128/JVI.01445-16
Su S, Rasquinha G, Du L, Wang Q, Xu W, Li W, Lu L, Jiang S (2019) A peptide-based HIV-1 fusion inhibitor with two tail-anchors and palmitic acid exhibits substantially improved in vitro and ex vivo anti-HIV-1 activity and prolonged in vivo half-life. Molecules 24(6):1134. https://doi.org/10.3390/molecules24061134
Umashankara M, McFadden K, Zentner I, Schön A, Rajagopal S, Tuzer F, Kuriakose SA, Contarino M, Lalonde J, Freire E, Chaiken I (2010) The active core in a triazole peptide dual-site antagonist of HIV-1 gp120. ChemMedChem 5(11):1871–1879. https://doi.org/10.1002/cmdc.201000222
Van Herrewege Y, Morellato L, Descours A, Aerts L, Michiels J, Heyndrickx L, Martin L, Vanham G (2008) Cd4 mimetic miniproteins: potent anti-HIV compounds with promising activity as microbicides. J Antimicrob Chemother 61(4):818–826. https://doi.org/10.1093/jac/dkn042
VanCompernolle SE, Taylor RJ, Oswald-Richter K, Jiang J, Youree BE, Bowie JH, Tyler MJ, Conlon JM, Wade D, Aiken C, Dermody TS, KewalRamani VN, Rollins-Smith LA, Unutmaz D (2005) Antimicrobial peptides from amphibian skin potently inhibit human immunodeficiency virus infection and transfer of virus from dendritic cells to T cells. J Virol 79(18):11598–11606. https://doi.org/10.1128/jvi.79.18.11598-11606.2005
VanCompernolle S, Smith PB, Bowie JH, Tyler MJ, Unutmaz D, Rollins-Smith LA (2015) Inhibition of HIV infection by caerin 1 antimicrobial peptides. Peptides 71:296–303. https://doi.org/10.1016/j.peptides.2015.05.004
Vita C, Drakopoulou E, Vizzavona J, Rochette S, Martin L, Ménez A, Roumestand C, Yang YS, Ylisastigui L, Benjouad A, Gluckman JC (1999) Rational engineering of a miniprotein that reproduces the core of the CD4 site interacting with HIV-1 envelope glycoprotein. Proc Natl Acad Sci U S A 96(23):13091–13096. https://doi.org/10.1073/pnas.96.23.13091
Wang RR, Yang LM, Wang YH, Pang W, Tam SC, Tien P, Zheng YT (2009) Sifuvirtide, a potent HIV fusion inhibitor peptide. Biochem Biophys Res Commun 382(3):540–544. https://doi.org/10.1016/j.bbrc.2009.03.057
Wang Q, Su S, Xue J, Yu F, Pu J, Bi W, Xia S, Meng Y, Wang C, Yang W, Xu W, Zhu Y, Zheng Q, Qin C, Jiang S, Lu L (2020) An amphipathic peptide targeting the gp41 cytoplasmic tail kills HIV-1 virions and infected cells. Sci Transl Med 12(546):eaaz2254. https://doi.org/10.1126/scitranslmed.aaz2254
Xie D, Yao C, Wang L, Min W, Xu J, Xiao J, Huang M, Chen B, Liu B, Li X, Jiang H (2010) An albumin-conjugated peptide exhibits potent anti-HIV activity and long in vivo half-life. Antimicrob Agents Chemother 54(1):191–196. https://doi.org/10.1128/AAC.00976-09
Xu W, Pu J, Su S, Hua C, Su X, Wang Q, Jiang S, Lu L (2019) Revisiting the mechanism of enfuvirtide and designing an analog with improved fusion inhibitory activity by targeting triple sites in gp41. AIDS 33(10):1545–1555. https://doi.org/10.1097/qad.0000000000002208
Yahi N, Fantini J, Mabrouk K, Tamalet C, de Micco P, van Rietschoten J, Rochat H, Sabatier JM (1994) Multibranched V3 peptides inhibit human immunodeficiency virus infection in human lymphocytes and macrophages. J Virol 68(9):5714–5720. https://doi.org/10.1128/jvi.68.9.5714-5720.1994
Yao X, Chong H, Zhang C, Waltersperger S, Wang M, Cui S, He Y (2012) Broad antiviral activity and crystal structure of HIV-1 fusion inhibitor sifuvirtide. J Biol Chem 287(9):6788–6796. https://doi.org/10.1074/jbc.M111.317883
Zanotto C, Calderazzo F, Dettin M, Di Bello C, Autiero M, Guardiola J, Chieco-Bianchi L, De Rossi A (1995) Minimal sequence requirements for synthetic peptides derived from the V3 loop of the human immunodeficiency virus type 1 (HIV-1) to enhance HIV-1 binding to cells and infection. Virology 206(2):807–816. https://doi.org/10.1006/viro.1995.1003
Zhu Y, Zhang X, Ding X, Chong H, Cui S, He J, Wang X, He Y (2018) Exceptional potency and structural basis of a T1249-derived lipopeptide fusion inhibitor against HIV-1, HIV-2, and simian immunodeficiency virus. J Biol Chem 293(14):5323–5334. https://doi.org/10.1074/jbc.RA118.001729
Zhu Y, Chong H, Yu D, Guo Y, Zhou Y, He Y (2019) Design and characterization of cholesterylated peptide HIV-1/2 fusion inhibitors with extremely potent and long-lasting antiviral activity. J Virol 93(11):e02312–e02318. https://doi.org/10.1128/jvi.02312-18
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2022 Springer Nature Singapore Pte Ltd.
About this chapter
Cite this chapter
Pu, J., Wang, Q., Jiang, S. (2022). Peptide-Based HIV Entry Inhibitors. In: Jiang, S., Lu, L. (eds) Virus Entry Inhibitors. Advances in Experimental Medicine and Biology, vol 1366. Springer, Singapore. https://doi.org/10.1007/978-981-16-8702-0_2
Download citation
DOI: https://doi.org/10.1007/978-981-16-8702-0_2
Published:
Publisher Name: Springer, Singapore
Print ISBN: 978-981-16-8701-3
Online ISBN: 978-981-16-8702-0
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)